Adaptive Clinical Trials

Clinical trials are rewriting their own rulebooks as they run, rather than sticking to a rigid plan set before a single patient is enrolled. This matters because the traditional approach to designing a trial forces researchers to lock in assumptions—about how big a treatment effect will be, how many patients are needed, or what dose to use—before any data exist. If those assumptions are wrong, the trial can fail unnecessarily, wasting time and money, or exposing more patients than needed to an ineffective treatment. The problem is not a lack of good drugs, but a rigid testing system that can miss them. If this research succeeds, trials will become adaptive: they can stop early if a treatment is clearly working or clearly not, adjust the number of patients mid-study, change doses, or identify which patient subgroups respond best. The goal is to answer the same scientific questions with fewer patients, while maintaining statistical rigour. This could make drug development faster, cheaper, and more ethical—not by changing the drugs, but by changing how we test them.